# **Health Products Regulatory Authority**

# **Summary of Product Characteristics**

#### **1 NAME OF THE MEDICINAL PRODUCT**

Foznol 1000 mg Chewable Tablets

### **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each chewable tablet contains 1000 mg of lanthanum (as lanthanum carbonate hydrate).

Excipient(s) with known effect: dextrates, containing glucose.

For the full list of excipients, see section 6.1.

# **3 PHARMACEUTICAL FORM**

Chewable tablets.

Product imported from Czech Republic:

White, round, flat, bevelled chewable tablets debossed with 'S405/1000' on one side.

#### **4 CLINICAL PARTICULARS**

As per PA23211/002/004

#### **5 PHARMACOLOGICAL PROPERTIES**

As per PA23211/002/004

#### **6 PHARMACEUTICAL PARTICULARS**

## 6.1 List of excipients

Dextrates Colloidal anhydrous silica Magnesium stearate

## 6.2 Incompatibilities

Not applicable.

#### 6.3 Shelf life

The shelf-life expiry date of this product is the date shown on the bottle and outer package of the product on the market in the country of origin.

## 6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

#### 6.5 Nature and contents of container

The tablets are supplied in white cylindrical HDPE bottles containing sealing cotton, with a polypropylene child safety thread cap and fuse. Multipack containing 90 (6 packs of 15) chewable tablets.

# 6.6 Special precautions for disposal

30 September 2022 CRN00D3CC Page 1 of 2

# 7 PARALLEL PRODUCT AUTHORISATION HOLDER

PCO Manufacturing Ltd., Unit 10, Ashbourne Business Park, Rath, Ashbourne, Co. Meath, Ireland.

## **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA0465/495/001

## 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 30<sup>th</sup> September 2022

10 DATE OF REVISION OF THE TEXT

30 September 2022 CRN00D3CC Page 2 of 2